Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puretech Health Plc ADR (NQ: PRTC )

27.07 +0.12 (+0.45%)
Streaming Delayed Price Updated: 3:57 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 121
Open 27.07
Bid (Size) 15.00 (1)
Ask (Size) 43.31 (2)
Prev. Close 26.95
Today's Range 27.07 - 27.07
52wk Range 18.15 - 38.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PureTech to Present at the Jefferies Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
From PureTech Health plc
Via Business Wire

Performance

YTD
-8.19%
-8.19%
1 Month
+5.13%
+5.13%
3 Month
-6.62%
-6.62%
6 Month
-15.41%
-15.41%
1 Year
+20.04%
+20.04%

More News

Read More
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
From PureTech Health plc
Via Business Wire
PureTech Health FY22 Revenue Declines 10.2% YoY, Here Are The Details
Via Benzinga
PureTech Announces Annual Results for Year Ended December 31, 2022
From PureTech Health plc
Via Business Wire
Earnings Scheduled For April 28, 2023
Via Benzinga
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
From PureTech Health plc
Via Business Wire
PureTech Health: Notice of Results
From PureTech Health plc
Via Business Wire
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
From Royalty Pharma plc
Via GlobeNewswire
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
From PureTech Health plc
Via Business Wire
PureTech to Present at the Barclays Global Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)
From PureTech Health plc
Via Business Wire
PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression
From PureTech Health plc
Via Business Wire
PureTech to Present at the SVB Securities Global Biopharma Conference
From PureTech Health plc
Via Business Wire
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
PureTech Provides End of Year Report on Key Progress
From PureTech Health plc
Via Business Wire
PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
From PureTech Health plc
Via Business Wire
PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
From PureTech
Via Business Wire
PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring
From PureTech Health plc
Via Business Wire
PureTech Announces New Therapeutic Candidate LYT-310, An Oral CBD Prodrug
Via Benzinga
PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform
From PureTech Health plc
Via Business Wire
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.